- What are Symptoms Treatment and Prognosis of Brainstem glioma?
- 2021 latest analysis of global CAR-T drugs and future development
- Should Johnson & Johnson COVID-19 vaccine be used for booster?
- Brazilian President will be sued as Homicide due to his COVID-19 policies?
- A school in Florida requires students to stay at home for 30 days after vaccination
- New COVID-19 variants in UK More contagious than Delta?
Roche PD-L1 monoclonal antibody Tecentreq reduces postoperative recurrence of lung cancer
Roche PD-L1: Tecentreq reduces postoperative recurrence of lung cancer. Lung cancer is one of the leading causes of cancer deaths worldwide.
On May 20, Roche announced that the PD-L1 monoclonal antibody Tecentreq (atelizumab) for the treatment of non-small cell lung cancer (NSCLC) Phase III clinical trial (IMpower010) had positive interim results.
IMpower010 is a global multi-center, open, randomized phase III clinical trial designed to evaluate atelizumab and best supportive care (BSC) treatment undergoing surgical resection and 4 cycles of cisplatin-based adjuvant chemotherapy Differences in efficacy and safety in patients with stage IB-IIIA non-small cell lung cancer.
A total of 1005 patients were enrolled in the study, who were randomly assigned to the atilizumab group or BSC group at a ratio of 1:1, and received up to 16 treatment courses. The primary endpoint was PD-L1 positive (PD-L1 expression ≥1%) stage II-IIIA patients, all randomized stage II-IIIA patients, and intention-to-treat (ITT) DFS in patients with stage IB-IIIA determined by the investigator. The key secondary endpoints are OS (overall survival) in overall and ITT IB-IIIA stage subjects.
In stage II-IIIA patients whose tumors express PD-L1≥1% (PD-L1 positive), compared with best supportive care (BSC), treatment with atilizumab after surgery and chemotherapy can make The recurrence or mortality of stage II-IIIA non-small cell lung cancer patients with PD-L1 expression ≥1% was reduced by 34% (HR=0.66, 95%CI: 0.50-0.88). This part of the population in the atelizumab group The bit disease-free survival (mDFS) has not been reached, while the mDFS in the BSC group was 35.3 months.
Among all randomized patients with stage II-IIIA, the median disease-free survival (mDFS) of the atilizumab group was 7 months longer than that of the BSC group (42.3 months VS 35.3 months). With a median follow-up of 32.2 months, atelizumab reduced the risk of recurrence or death in this population by 21% (HR=0.79, 95%CI: 0.64-0.96).
In terms of safety, consistent with the expected results, the incidence of overall adverse events and grade 3-4 adverse events in the atilizumab group was higher than that in the BSC group.
Roche will announce the detailed clinical data of the trial at the ASCO meeting on June 6.
Lung cancer is one of the leading causes of cancer deaths worldwide, causing 1.8 million deaths each year. NSCLC is the most common type, accounting for about 85% of all lung cancers. Adjuvant therapy can reduce the risk of recurrence and provide the best chance of cure.
Nevertheless, about half of patients with stage I-III NSCLC will eventually relapse after receiving treatment. Atelizumab is the first immunosuppressant that has been proven effective in reducing the recurrence rate in phase III clinical trials.
(source:internet, reference only)